Endometrial Cancer Clinical Trials in Boston, Massachusetts

34 studies are recruiting for endometrial cancer in Boston, Massachusetts right now. Each one is listed on ClinicalTrials.gov, the public registry the research teams themselves file with. TrialBoost is not a doctor, a research site, or a study sponsor: the research team decides who takes part.

Search these by distance from you

Studies, page 2

1. Menstrual Cup for Early Endometrial Cancer Detection in Lynch Syndrome

   Study Goal: This pilot study wants to find out if using a menstrual cup can be a good, non-invasive way to collect samples from the lining of the uterus (called the endometrium) to help screen for endometrial cancer. This is especially important for women who have a higher chance of getting this ca…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Run by

   Jessica D. St. Laurent, MD

   See if you can join NCT07220239 on ClinicalTrials.gov

2. Dose Escalation and Dose Expansion Study of MDX2001 in Patients With Advanced Solid Tumors

   This study is designed to characterize the safety, tolerability, and anti-tumor activity of MDX2001 in patients with advanced solid tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   6 in total

   Run by

   ModeX Therapeutics, An OPKO Health Company

   See if you can join NCT06239194 on ClinicalTrials.gov

3. A Study of Targeted Agents for Patients With Recurrent or Persistent Endometrial Cancer

   This is a Phase IB/II multi-cohort study designed to evaluate the efficacy and safety of targeted agents with or without cancer immune checkpoint therapy with atezolizumab in participant with recurrent and/or persistent endometrial cancer. The main protocol provides a platform for genomic screening…

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   21 in total

   Run by

   Alliance Foundation Trials, LLC.

   See if you can join NCT04486352 on ClinicalTrials.gov

4. A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

   This is a two-part, open-label, multicenter, dose escalation and dose expansion study designed to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and anti- tumor activity of ETX-19477, a novel reversible small molecule inhibitor of PARG.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   14 in total

   Run by

   858 Therapeutics, Inc.

   See if you can join NCT06395519 on ClinicalTrials.gov

5. Exercise as a Preventive Agent to Combat Immobility in Patients With Ovarian or Endometrial Cancers Receiving Chemotherapy

   The purpose of this research is to determine whether a 16-week virtually supervised aerobic and resistance exercise program is feasible in patients receiving first-line chemotherapy after surgery for ovarian or endometrial cancer and if it will improve lower extremity function (function of the legs…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT04997096 on ClinicalTrials.gov

6. Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

   The objective of this study is to evaluate the safety, tolerability, and efficacy of BL-B01D1 in patients with Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors.

   Stage

   Phase 1

   Ages

   18 and older

   Site

   Massachusetts General Hospital, Boston, Massachusetts

   Locations

   39 in total

   Run by

   SystImmune Inc.

   See if you can join NCT05983432 on ClinicalTrials.gov

7. Avelumab and M1774 in ARID1A-mutated Endometrial Cancer

   The purpose of this research study is to see if the combination of study drugs avelumab and M1774 is effective and safe for participants with endometrial cancer. The names of the study drugs involved in this study are: * Avelumab (a type of human IgG1 antibody) * M1774 (a type of ATR inhibitor)

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Dana-Farber Cancer Institute, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Panagiotis Konstantinopoulos, MD, PhD

   See if you can join NCT06518564 on ClinicalTrials.gov

8. Belzutifan in Recurrent Clear Cell Carcinoma of Gynecologic Origin

   The purpose of this research study is to see if the study drug Belzutifan is effective and safe for participants with clear cell gynecologic malignancy, including but not limited to, ovarian cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, or endometriosis-related cancer.…

   Stage

   Phase 2

   Ages

   18 and older

   Site

   Brigham and Women's Hospital, Boston, Massachusetts

   Locations

   2 in total

   Run by

   Dana-Farber Cancer Institute

   See if you can join NCT06677190 on ClinicalTrials.gov

9. Comprehensive Outcomes for After Cancer Health

   This study intends to explore feasibility, acceptability, and outcomes related to the use of a digital health coaching intervention for individuals who have completed primary therapy for cancer. Up to 625 individuals with diverse cancer diagnoses will be enrolled across up to 8 clinical sites to pa…

   Stage

   Not phased

   Ages

   18 and older

   Site

   Dana Farber Cancer Institute, Boston, Massachusetts

   Locations

   7 in total

   Run by

   Pack Health

   See if you can join NCT05349227 on ClinicalTrials.gov